Viracta Therapeutics’ (VIRX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Viracta Therapeutics (NASDAQ:VIRX) in a report published on Tuesday, Benzinga reports. HC Wainwright currently has a $4.00 target price on the stock.

Viracta Therapeutics Trading Down 2.9 %

Shares of NASDAQ:VIRX opened at $0.91 on Tuesday. Viracta Therapeutics has a 12 month low of $0.43 and a 12 month high of $2.38. The company has a 50-day moving average price of $0.91 and a 200 day moving average price of $0.70. The company has a market cap of $35.70 million, a price-to-earnings ratio of -0.69 and a beta of 0.93.

Viracta Therapeutics (NASDAQ:VIRX) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.05). As a group, equities analysts forecast that Viracta Therapeutics will post -1.28 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in Viracta Therapeutics by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 1,161,280 shares of the company’s stock worth $662,000 after purchasing an additional 13,368 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Viracta Therapeutics by 7.6% in the second quarter. Renaissance Technologies LLC now owns 134,799 shares of the company’s stock worth $190,000 after purchasing an additional 9,500 shares during the last quarter. BlackRock Inc. lifted its stake in Viracta Therapeutics by 2.8% in the second quarter. BlackRock Inc. now owns 460,235 shares of the company’s stock worth $649,000 after purchasing an additional 12,434 shares during the last quarter. Jane Street Group LLC lifted its stake in Viracta Therapeutics by 129.2% in the first quarter. Jane Street Group LLC now owns 55,465 shares of the company’s stock worth $88,000 after purchasing an additional 31,264 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in Viracta Therapeutics by 81.3% in the first quarter. Bank of America Corp DE now owns 23,241 shares of the company’s stock worth $37,000 after purchasing an additional 10,422 shares during the last quarter. Institutional investors own 31.37% of the company’s stock.

About Viracta Therapeutics

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.